Physician profile
Keith L Fuller
NPI 1730125527
$12,420.52
in general payments reported to CMS, 2019-2025
53 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,508 · 2020: $1,508 · 2021: $1,908 · 2022: $1,989 · 2023: $2,291 · 2024: $1,700 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,467 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,467.31 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,506.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,376.11 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,041.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $1,041.06 | 2021-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $798.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $488.50 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Teva Pharmaceuticals USA, INC. | $454.71 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Amgen INC. | $448.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $389.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.61 | 2019-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $294.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.98 | 2021-2025 | |
| Pfizer INC. | $210.49 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $198.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $188.08 | 2020-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.